EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Immunotherapy in Pancreatic Cancer

Ahmad Hegazi iD, Lauren Elizabeth Rager iD, Dean Edward Watkins iD, Kuo-Hui Su iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111560 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ahmad Hegazi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Cancer Biology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH 43614, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Toledo Startup Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer remains one of the deadliest malignancies, with a consistently low five-year survival rate for the past several decades. This is in stark contrast to other cancers, which have seen significant improvement in survival and prognosis due to recent developments in therapeutic modalities. These modest improvements in pancreatic cancer outcomes have primarily resulted from minor advances in cytotoxic chemotherapeutics, with limited progress in other treatment approaches. A major focus of current therapeutic research is the further development of immunomodulatory therapies characterized by antibody-based approaches, cellular therapies, and vaccines. Although initial results utilizing immunotherapy in pancreatic cancer have been mixed, recent clinical trials have demonstrated significant improvements in patient outcomes. In this review, we detail these three approaches to immunomodulation, highlighting their common targets and distinct shortcomings, and we provide a narrative summary of completed and ongoing clinical trials that utilize these approaches to immunomodulation. Within this context, we aim to inform future research efforts by identifying promising areas that warrant further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsImmunotherapyHumansCancer VaccinesClinical Trials as TopicAnimalsImmunomodulation

Stichwörter der Autor:innen

antibody therapycellular therapyclinical trialimmune checkpoint inhibitorimmunotherapypancreatic cancervaccine therapy

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Department of Cell and Cancer Biology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH 43614, USA.

ORCID-Profile: Ahmad Hegazi, Lauren Elizabeth Rager, Dean Edward Watkins, Kuo-Hui Su

Förderung

  • The University of Toledo Startup Fund

Zitieren

APA

Hegazi, A., Rager, L. E., Watkins, D. E., & Su, K. H. (2024). Advancing Immunotherapy in Pancreatic Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111560

Vancouver

Hegazi A, Rager LE, Watkins DE, Su KH. Advancing Immunotherapy in Pancreatic Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111560

BibTeX
@article{Hegazi2024,
  author = {Hegazi, Ahmad and Rager, Lauren Elizabeth and Watkins, Dean Edward and Su, Kuo-Hui},
  title = {Advancing Immunotherapy in Pancreatic Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111560}
}
Kostenlos starten →